Subject: From insurance commissioner to healthcare fraudster

February 28, 2025

Dear Friend,


From insurance commissioner to healthcare fraudster to federal prison inmate. Not the usual career path, for sure.

 

That was the subject of Monday's blog post, From Insurance Watchdog to Prisoner: A Cautionary Tale for Healthcare Professionals. You can follow the link to read the post online, or just keep reading.


John Oxendine spent 16 years as Georgia’s Insurance Commissioner, wielding influence and chasing a gubernatorial dream.


But in a twist ripped from a legal thriller, last year, Oxendine pleaded guilty to conspiracy to commit healthcare fraud. His crime? Peddling unnecessary medical tests through physicians, submitting fraudulent insurance claims, and pocketing kickbacks from a medical lab. The result: a 3.5-year federal prison sentence and a forced surrender of his law license.


So, why should physicians care about the missteps of a disgraced politician?

 

When Kickbacks Come Knocking: What Oxendine’s Case Teaches Us

 

Here’s the hard truth: Schemes like the one that brought Oxendine down aren’t rare. They lurk in glossy marketing pitches, seemingly innocuous consulting offers, and partnerships that promise too-good-to-be-true financial returns.

 

Oxendine’s scheme, perpetrated with his partner in crime, Dr. Jeffrey Gallups, a physician who got his own three-year stint in prison, involved encouraging physicians associated with Gallups’ ENT practice to order medically unnecessary tests from a lab that paid kickbacks to Oxendine and Gallups.

 

This wasn’t some elaborate, Ocean’s Eleven-level scheme. It was basic greed—padding insurance claims—dressed up in a lab coat.

 

The Hidden Cost of Turning a Blind Eye

 

The lesson? If someone’s offering a deal that sounds like easy money, it’s probably illegal money.

 

Oxendine’s downfall didn’t start with massive fraud; it likely began with a series of choices that seemed minor at the time. Many healthcare fraud cases start with small, seemingly harmless decisions—a little “consulting money” on the side, a stipend for a “speech” at a dinner with 5 others at the table, a few extra lab tests.

 

But those small cracks can widen fast and before you know it, a federal investigator is knocking on your door.

 

In healthcare, the stakes aren’t just financial—they’re criminal. You won’t just pay fines; you’ll face prison time, lose your license, and become front-page news for all the wrong reasons.

 

Practical Steps to Avoid the Pitfalls

 

If there’s one key takeaway from Oxendine’s story, it’s that you need more than good intentions to stay out of legal quicksand. Here are some things to keep in mind:

 

  1. Scrutinize Every Financial Relationship: If someone approaches you with a financial opportunity tied to patient referrals or test orders, assume it requires legal review.

  2. Know the Rules: Familiarize yourself with federal laws like the Anti-Kickback Statute and Stark—and don’t ignore state counterparts.

  3. Document Everything: Clear, thorough, and truthful documentation can be crucial if an investigation ever comes your way.

  4. Audit Regularly: Set up internal checks and balances to catch problems before the government—or a whistleblower—does.

  5. Trust Your Instincts: If something feels off, it probably is. Investigate first; regret later isn’t a great legal strategy.

Stay sharp. Stay honest. And remember—someone else’s bad idea can very quickly become your nightmare.

BOI Reporting Back on With a Caveat on Timing


The immediately prior nationwide injunction against mandatory BOI reporting pursuant to the Corporate Transparency Act, in place in connection with Smith v. United States Department of Treasury, was lifted earlier this week.

 

The deadline for BOI reporting to FinCEN is now March 21, 2025.

 

There are, however, pending updates to the BOI reporting rule and pending legislation (enacted by the House but not yet by the Senate or signed into law), that might cause you to choose to delay filing until closer to the deadline. The timing issue depends on your situation; for advice on filing, contact Mark.

Blue Cross Blue Shield Antitrust Class Action Lawsuit

 

There’s a lot of chatter about the pending settlement of the Blue Cross Blue Shield antitrust class action case, in particular, the March 4, 2025, deadline to opt out of the class.


Every class member, whether a facility or a "provider", needs to assess whether or not to opt out and whether or not to file a claim. Inaction has legal consequences.


The decision is more complicated than simply weighing one’s own potential damages and comparing them against an impossible to exactly quantify potential share in the class action settlement fund.


Contact Mark to discuss weighing the opt-out decision or in connection with the claims process which involves issues not completely apparent on its face. 

UPCOMING PRESENTATION:


Books & Publications

Browse all of our complimentary resources on our website.

©2025 Mark F. Weiss. All Rights Reserved